Abstract
Myelodysplastic syndrome (MDS) progresses into acute leukaemia with a variable time course. We analysed 45 newly diagnosed patients and found that the expression of the Src homology 2 domain-containing tyrosine phosphatase 1 (SHP1) had a significant impact on disease severity, progression and overall prognosis. Global or lineage-specific loss of SHP1 was observed by immunohistochemistry in bone marrow biopsies of MDS patients who progressed rapidly (P = 0.0021) and had shorter survival (P < 0.001). Cox regression analysis demonstrated that SHP1 expression in megakaryocytes had prognostic relevance for time to progression (P = 0.009) and overall survival (P = 0.001).
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Biomarkers / metabolism
-
Biopsy
-
Bone Marrow / enzymology*
-
Disease Progression
-
Female
-
Humans
-
Immunoenzyme Techniques
-
Intracellular Signaling Peptides and Proteins
-
Male
-
Middle Aged
-
Myelodysplastic Syndromes / enzymology*
-
Prognosis
-
Protein Phosphatase 1
-
Protein Tyrosine Phosphatase, Non-Receptor Type 6
-
Protein Tyrosine Phosphatases / metabolism*
-
Survival Analysis
Substances
-
Biomarkers
-
Intracellular Signaling Peptides and Proteins
-
Protein Phosphatase 1
-
PTPN6 protein, human
-
Protein Tyrosine Phosphatase, Non-Receptor Type 6
-
Protein Tyrosine Phosphatases